Searle & Co’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $36.8K | Hold |
86,250
| – | – | 0.01% | 194 |
|
|
2026
Q1 | $69K | Hold |
86,250
| – | – | 0.02% | 192 |
|
|
2025
Q4 | $112K | Hold |
86,250
| – | – | 0.03% | 185 |
|
|
2025
Q3 | $109K | Hold |
86,250
| – | – | 0.03% | 183 |
|
|
2025
Q2 | $179K | Hold |
86,250
| – | – | 0.05% | 179 |
|
|
2025
Q1 | $190K | Hold |
86,250
| – | – | 0.05% | 172 |
|
|
2024
Q4 | $132K | Hold |
86,250
| – | – | 0.04% | 174 |
|
|
2024
Q3 | $172K | Buy |
86,250
+75,250
| +684% | +$180K | 0.04% | 166 |
|
|
2024
Q2 | $38.5K | Sell |
11,000
-75,250
| -87% | -$231K | 0.01% | 181 |
|
|
2024
Q1 | $239K | Buy |
86,250
+1,000
| +1% | +$2.51K | 0.06% | 149 |
|
|
2023
Q4 | $145K | Hold |
85,250
| – | – | 0.04% | 155 |
|
|
2023
Q3 | $87.8K | Buy |
85,250
+7,000
| +9% | +$10K | 0.03% | 141 |
|
|
2023
Q2 | $130K | Buy |
78,250
+15,000
| +24% | +$26.8K | 0.04% | 149 |
|
|
2023
Q1 | $151K | Buy |
63,250
+30,000
| +90% | +$75.1K | 0.05% | 143 |
|
|
2022
Q4 | $83.1K | Hold |
33,250
| – | – | 0.03% | 146 |
|
|
2022
Q3 | $140K | Hold |
33,250
| – | – | 0.05% | 139 |
|
|
2022
Q2 | $93K | Hold |
33,250
| – | – | 0.04% | 146 |
|
|
2022
Q1 | $190K | Sell |
33,250
-14,500
| -30% | -$106K | 0.07% | 150 |
|
|
2021
Q4 | $436K | Hold |
47,750
| – | – | 0.16% | 106 |
|
|
2021
Q3 | $510K | Buy |
47,750
+500
| +1% | +$6.09K | 0.21% | 89 |
|
|
2021
Q2 | $733K | Buy |
47,250
+10,000
| +27% | +$159K | 0.3% | 75 |
|
|
2021
Q1 | $604K | Sell |
37,250
-500
| -1% | -$8.91K | 0.27% | 81 |
|
|
2020
Q4 | $799K | Sell |
37,750
-750
| -2% | -$13K | 0.38% | 67 |
|
|
2020
Q3 | $571K | Buy |
38,500
+9,500
| +33% | +$148K | 0.31% | 75 |
|
|
2020
Q2 | $427K | Sell |
29,000
-500
| -2% | -$8.21K | 0.25% | 82 |
|
|
2020
Q1 | $346K | Buy |
29,500
+17,000
| +136% | +$320K | 0.25% | 82 |
|
|
2019
Q4 | $294K | Buy |
12,500
+1,500
| +14% | +$33.2K | 0.16% | 107 |
|
|
2019
Q3 | $204K | Sell |
11,000
-10,150
| -48% | -$187K | 0.12% | 128 |
|
|
2019
Q2 | $393K | Buy |
+21,150
| New | +$422K | 0.24% | 92 |
|
|
2017
Q3 | – | Sell |
-26,500
| Closed | -$367K | – | 129 |
|
|
2017
Q2 | $367K | Buy |
26,500
+3,000
| +13% | +$43.5K | 0.25% | 92 |
|
|
2017
Q1 | $353K | Buy |
+23,500
| New | +$325K | 0.25% | 96 |
|
Other funds holding HRTX
VCIM
TC
TCM
JAM
Searle & Co's HRTX Position: Q2 2026 in Review
Searle & Co held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 86,250 shares worth $36.8K. The position accounts for 0.01% of the portfolio, ranked #194.
Searle & Co first reported a position in HRTX in Q1 2017 and has held it in 31 quarters since. The position peaked at $799K in Q4 2020. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.
- Searle & Co held 86,250 shares of Heron Therapeutics worth $36.8K as of Q2 2026.
- Searle & Co left its Heron Therapeutics share count unchanged in Q2 2026.
- Heron Therapeutics made up 0.01% of Searle & Co's portfolio in Q2 2026, its #194 holding.
- Searle & Co first reported a position in Heron Therapeutics in Q1 2017 and has held it in 31 quarters since.
- Searle & Co's Heron Therapeutics position peaked at $799K in Q4 2020.
- 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.
Based on Searle & Co's 13F filing for Q2 2026, filed 27 Jul 2026.